No records
|
660 |
Ramani S., McKimm J., Forrest K., Hays R., Bishop J., Thampy H., Findyartini A., Nadarajah V.D., Kusurkar R., Wilson K., Filipe H., Kachur E. |
56186462600;26433565200;26635053400;7202509928;8406026800;55349958700;56543777300;14048599600;6603461994;56926010000;36657108400;6603938626; |
Co-creating scholarship through collaborative writing in health professions education: AMEE Guide No. 143 |
2021 |
Medical Teacher |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120044813&doi=10.1080%2f0142159X.2021.1993162&partnerID=40&md5=3773bd230107ba738a15f75175eba901 |
Harvard Medical School, Boston, United States; Manchester Medical School, University of Manchester, Manchester, United Kingdom; Swansea University Medical School, United Kingdom; Bond University, Queensland, Australia; James Cook University College of Medicine and Dentistry, James Cook University, Townsville, Australia; Department of Medical Education, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; International Medical University, Kuala Lumpur, Malaysia; Amsterdam UMC, Research in Education, Faculty of Medicine, Vrije Universiteit, Amsterdam, Netherlands; Dalhousie University, Halifax, NS, Canada; Hospital Egas Moniz, West Lisbon Hospitals Center (NHS), University of Lisbon, Lisboa, Portugal; Medical Education Development, Global Consulting, New York, NY, United States |
Ramani, S., Harvard Medical School, Boston, United States, Manchester Medical School, University of Manchester, Manchester, United Kingdom; McKimm, J., Swansea University Medical School, United Kingdom; Forrest, K., Bond University, Queensland, Australia; Hays, R., James Cook University College of Medicine and Dentistry, James Cook University, Townsville, Australia; Bishop, J., Bond University, Queensland, Australia; Thampy, H., Manchester Medical School, University of Manchester, Manchester, United Kingdom; Findyartini, A., Department of Medical Education, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Nadarajah, V.D., International Medical University, Kuala Lumpur, Malaysia; Kusurkar, R., Amsterdam UMC, Research in Education, Faculty of Medicine, Vrije Universiteit, Amsterdam, Netherlands; Wilson, K., Dalhousie University, Halifax, NS, Canada; Filipe, H., Hospital Egas Moniz, West Lisbon Hospitals Center (NHS), University of Lisbon, Lisboa, Portugal; Kachur, E., Medical Education Development, Global Consulting, New York, NY, United States |
This AMEE guide provides a robust framework and practical strategies for health professions educators to enhance their writing skills and engage in successful scholarship within a collaborative writing team. Whether scholarly output involves peer-reviewed articles, book chapters, blogs and online posts, online educational resources, collaborative writing requires more than the usual core writing skills, it requires teamwork, leadership and followership, negotiation, and conflict resolution, mentoring and more. Whilst educators can attend workshops or courses to enhance their writing skills, there may be fewer opportunities to join a community of scholars and engage in successful collaborative writing. There is very little guidance on how to find, join, position oneself and contribute to a writing group. Once individuals join a group, further questions arise as to how to contribute, when and whom to ask for help, whether their contribution is significant, and how to move from the periphery to the centre of the group. The most important question of all is how to translate disparate ideas into a shared key message and articulate it clearly. In this guide, we describe the value of working within a collaborative writing group; reflect on principles that anchor the concept of writing as a team and guide team behaviours; suggest explicit strategies to overcome challenges and promote successful writing that contributes to and advances the field; and review challenges to starting, maintaining, and completing writing tasks. We approach writing through three lenses: that of the individual writer, the writing team, and the scholarly product, the ultimate goal being meaningful contributions to the field of Health Professions Education. © 2021 AMEE. |
collaborative/peer-to-peer; Continuing; leadership; mentoring; staff development |
|
Taylor and Francis Ltd. |
0142159X |
|
|
Article |
Q1 |
1355 |
2689 |
|
|
661 |
Andreas A.M., Djuwita R., Helda H., Sekartni R., Suradijono S.H.R., Wiguna T., Tulaar A.B.M., Kristianto Y., Hendrik H. |
57356220700;56586138300;57195467249;57355240300;57209473358;57356086800;24330360800;57356220800;57355801600; |
Massage therapy can prevent the risk of autism spectrum disorders in children |
2021 |
Open Access Macedonian Journal of Medical Sciences |
9 |
|
|
1556 |
1560 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120032396&doi=10.3889%2foamjms.2021.7436&partnerID=40&md5=ca9744bb24e561c7ddfc3916dd11ecc2 |
Faculty of Public Health, University of Indonesia, Jakarta, Indonesia; Department of Pediatrics and Development, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Developmental Psychology, Faculty of Psychology, University of Indonesia, Jakarta, Indonesia; Department of Child Psychiatry, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Medical Rehabilitation, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Health Polytechnic, Ministry of Health Jakarta 1, Jakarta, Indonesia; Department of Physiotherapy, Health Polytechnic, Ministry of Health Makassar, Makassar, Indonesia |
Andreas, A.M., Faculty of Public Health, University of Indonesia, Jakarta, Indonesia; Djuwita, R., Faculty of Public Health, University of Indonesia, Jakarta, Indonesia; Helda, H., Faculty of Public Health, University of Indonesia, Jakarta, Indonesia; Sekartni, R., Department of Pediatrics and Development, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Suradijono, S.H.R., Department of Developmental Psychology, Faculty of Psychology, University of Indonesia, Jakarta, Indonesia; Wiguna, T., Department of Child Psychiatry, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Tulaar, A.B.M., Department of Medical Rehabilitation, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Kristianto, Y., Health Polytechnic, Ministry of Health Jakarta 1, Jakarta, Indonesia; Hendrik, H., Department of Physiotherapy, Health Polytechnic, Ministry of Health Makassar, Makassar, Indonesia |
BACKGROUND: The prevalence of human beings with autism spectrum issues in some parts of the world tends to make bigger, in Indonesia alone, accurate and complete data and information from human beings with autism spectrum disorders (ASD) are nonetheless missing, so it is feared that many children with risk symptoms of ASD do not get treatment early. AIM: This research aims to prevent the risk of ASD in children through making use of massage therapy remedies based on evaluation of the Modified Checklist for Autism in Toddler (modified Chat [M-Chat]) ratings. METHODS: This research is a quasi-experimental study with a time series design which was carried out from May 2019 to March 2020 at three health centers in the city of Jakarta. The analysis was carried out before and after the application of massage in a time series of four periods on ten children aged 18–36 months with M-Chat scores, and then analyzed by receiver operating characteristics to obtain a cutoff point to determine the risk status of ASD. RESULTS: The results showed that there was an effect of massage therapy on the M-Chat score of children with ASD risk p = 0.004 < 0.05 and changes in the M-Chat score of children with ASD risk experienced significant changes after massage in the third and fourth therapy periods with p = 0.005 and p = 0.007 < 0.05. CONCLUSION: The results show that massage therapy can prevent of autism spectrum issues in children based on the Modified Checklist for Autism in Toddler (M-Chat). © 2021 Andy Martahan Andreas, Ratna Djuwita, Helda Helda, Rini Sekartni, Sri Hartati R. Suradijono, Thjin Wiguna, Angela B. M. Tulaar, Yusuf Kristianto, Hendrik Hendrik. |
Autism spectrum disorders; Babies; Massage therapy; Modified checklist for autism in toddler |
Article; autism; cesarean section; checklist; child; chromosome aberration; female; health center; human; human experiment; Indonesia; male; massage; pH; predictive value; preschool child; prevalence; prospective study; QT interval; quasi experimental study; receiver operating characteristic; scoring system; sensitivity and specificity; time series analysis; toddler |
Scientific Foundation SPIROSKI |
18579655 |
|
|
Article |
Q3 |
288 |
15252 |
|
|
662 |
Ta J.W.C., Chew D.P., Tsui K.L., Tan D., Duplyakov D., Hammoudeh A., Zhang B., Li Y., Xu K., Ong P.J., Firman D., Gamra H., Almahmeed W., Dalal J., Tam L.-W., Steg G., Nguyen Q.N., Ako J., Al Suwaidi J., Chan M., Sobhy M., Shehab A., Buddhari W., Wang Z., Fong A.Y.Y., Karadag B., Kim B.-K., Baber U., Chin C.T., Han Y.L. |
57354736300;7102026332;7101671562;50263435900;6506125408;8088443300;56637270100;55914058500;56510776700;7102312670;54898724100;7004594521;6506558682;7004278395;56585509700;57197860836;39962151600;6701389098;6603728555;23388249600;55345664600;6603838351;57192991797;8875501800;14321654600;56243107600;35189204900;16047315200;57226594604;57211831338; |
2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations |
2021 |
European Cardiology Review |
16 |
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119968735&doi=10.15420%2fecr.2021.35&partnerID=40&md5=0f474aea7166811035b920e727476fae |
National Heart Centre, Singapore; Sengkang General Hospital, Singapore; College of Medicine and Public Health, Flinders University, Adelaide, Australia; Pamela Youde Nethersole Eastern Hospital, Hong Kong; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore; Samara Regional Cardiology Dispensary, Samara, Russian Federation; Cardiology Department, Istishari Hospital, Amman, Jordan; Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, China; Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China; Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Heart Specialist International, Mount Elizabeth Novena Hospital, Singapore; Tan Tock Seng Hospital, Singapore; Harapan Kita National Cardiovascular Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia Harapan Kita, Jakarta, Indonesia; Cardiology Department, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia; Cleveland Clinic Abu Dhabi, United Arab Emirates; Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India; Kwong Wah Hospital, Hong Kong; Department of Cardiology, Hôpital Bichat, Paris, France; Department of Cardiology, Hanoi Medical University, Hanoi, Viet Nam; Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Adult Cardiology, Hamad Medical Corporation, Doha, Qatar; National University Heart Centre, Singapore; Faculty of Medicine, Alexandria University, Egypt; College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Sarawak Heart Centre, Kota Samarahan, Malaysia; Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States |
Ta, J.W.C., National Heart Centre, Singapore, Sengkang General Hospital, Singapore; Chew, D.P., College of Medicine and Public Health, Flinders University, Adelaide, Australia; Tsui, K.L., Pamela Youde Nethersole Eastern Hospital, Hong Kong; Tan, D., Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore; Duplyakov, D., Samara Regional Cardiology Dispensary, Samara, Russian Federation; Hammoudeh, A., Cardiology Department, Istishari Hospital, Amman, Jordan; Zhang, B., Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, China; Li, Y., Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China; Xu, K., Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Ong, P.J., Heart Specialist International, Mount Elizabeth Novena Hospital, Singapore, Tan Tock Seng Hospital, Singapore; Firman, D., Harapan Kita National Cardiovascular Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia Harapan Kita, Jakarta, Indonesia; Gamra, H., Cardiology Department, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia; Almahmeed, W., Cleveland Clinic Abu Dhabi, United Arab Emirates; Dalal, J., Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India; Tam, L.-W., Kwong Wah Hospital, Hong Kong; Steg, G., Department of Cardiology, Hôpital Bichat, Paris, France; Nguyen, Q.N., Department of Cardiology, Hanoi Medical University, Hanoi, Viet Nam; Ako, J., Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Al Suwaidi, J., Adult Cardiology, Hamad Medical Corporation, Doha, Qatar; Chan, M., National University Heart Centre, Singapore; Sobhy, M., Faculty of Medicine, Alexandria University, Egypt; Shehab, A., College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; Buddhari, W., King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Wang, Z., Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Fong, A.Y.Y., Sarawak Heart Centre, Kota Samarahan, Malaysia; Karadag, B., Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; Kim, B.-K., Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; Baber, U., University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Chin, C.T., National Heart Centre, Singapore; Han, Y.L., Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China |
Advanced age, diabetes, and chronic kidney disease not only increase the risk for ischaemic events in chronic coronary syndromes (CCS) but also confer a high bleeding risk during antiplatelet therapy. These special populations may warrant modification of therapy, especially among Asians, who have displayed characteristics that are clinically distinct from Western patients. Previous guidance has been provided regarding the classification of high-risk CCS and the use of newer-generation P2Y12inhibitors (i.e. ticagrelor and prasugrel) after acute coronary syndromes (ACS) in Asia. The authors summarise evidence on the use of these P2Y12inhibitors during the transition from ACS to CCS and among special populations. Specifically, they present recommendations on the roles of standard dual antiplatelet therapy, shortened dual antiplatelet therapy and single antiplatelet therapy among patients with coronary artery disease, who are either transitioning from ACS to CCS; elderly; or with chronic kidney disease, diabetes, multivessel coronary artery disease and bleeding events during therapy. © 2021 Radcliffe Group Ltd. All rights reserved. |
Asia; Comorbidity; Consensus; Dual antiplatelet therapy; Myocardial ischaemia; Platelet aggregation inhibitors |
|
Radcliffe Medical Media |
17583756 |
|
|
Article |
Q2 |
864 |
5422 |
|
|
663 |
Mangunatmadja I., Indra R.M., Widodo D.P., Rafli A. |
57195717216;57222298152;57215087823;57210824944; |
Risk Factors for Drug Resistance in Epileptic Children with Age of Onset above Five Years: A Case-Control Study |
2021 |
Behavioural Neurology |
2021 |
|
9092824 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119934233&doi=10.1155%2f2021%2f9092824&partnerID=40&md5=74ddaa54df43f8e9dd4e310b0bf1246c |
Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Child Health, Mohammad Hoesin General Hospital, Universitas Sriwijaya, Medical School, Palembang, Indonesia |
Mangunatmadja, I., Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Indra, R.M., Department of Child Health, Mohammad Hoesin General Hospital, Universitas Sriwijaya, Medical School, Palembang, Indonesia; Widodo, D.P., Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rafli, A., Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Background. Children with epilepsy with onset above five years encompass distinct epidemiological and clinical characteristics that may have specific risk factors for resistance to antiseizure medications (ASMs). Studies on this age group are limited. Purpose. To identify risk factors for drug resistance in children with epilepsy with the age of onset above five years. Methods. A case-control study was conducted on children with epilepsy with the age of onset above five years visiting the Pediatric Neurology Clinic of Cipto Mangunkusumo and Mohammad Hoesin Hospital between September 2015 and August 2016. Cases consisted of drug-resistant children while control consisted of drug-responsive children according to 2010 ILAE classification. Risk factors studied include onset, number of seizures, illness duration before treatment, cause, seizure type, status epilepticus, initial and evolution of EEG, brain imaging, and initial treatment response. Results. Thirty-two pairs of children were included in the study. After logistic regression analysis, symptomatic etiology and failure to achieve early response to treatment were found to be associated with drug resistance with adjusted OR of 84.71 (95% CI: 5.18-1359.15) and 72.55 (95% CI: 7.08-743.85), respectively. Conclusion. Poor initial response to ASM and symptomatic etiology are independent risk factors for drug resistance in children with epilepsy with the age of onset above five years. © 2021 Irawan Mangunatmadja et al. |
|
anticonvulsive agent; case control study; child; drug resistance; epilepsy; human; onset age; preschool child; risk factor; Age of Onset; Anticonvulsants; Case-Control Studies; Child; Child, Preschool; Drug Resistance; Epilepsy; Humans; Risk Factors |
Hindawi Limited |
09534180 |
|
34804259 |
Article |
Q2 |
859 |
5468 |
|
|
664 |
Han W.M., Law M.G., Choi J.Y., Ditangco R., Kumarasamy N., Chaiwarith R., Ly P.S., Khusuwan S., Merati T.P., Do C.D., Yunihastuti E., Azwa I., Lee M.-P., Pham T.N., Chan Y.-J., Kiertiburanakul S., Ng O.T., Tanuma J., Pujari S., Zhang F., Gani Y., Mave V., Ross J., Avihingsanon A., Ly P.S., Khol V., Zhang F.J., Zhao H.X., Han N., Lee M.P., Li P.C.K., Kwong T.S., Li T.H., Kumarasamy N., Ezhilarasi C., Pujari S., Joshi K., Gaikwad S., Chitalikar A., Sangle S., Mave V., Marbaniang I., Nimkar S., Merati T.P., Wirawan D.N., Yuliana F., Yunihastuti E., Widhani A., Maria S., Karjadi T.H., Tanuma J., Oka S., Nishijima T., Choi J.Y., Na S., Kim J.M., Gani Y.M., Rudi N.B., Azwa I., Kamarulzaman A., SyedOmar S.F., Ponnampalavanar S., Ditangco R., Pasayan M.K., Mationg M.L., Chan Y.J., Ku W.W., Wu P.C., Ke E., Ng O.T., Lim P.L., Lee L.S., Yap T., Ng O.T., Avihingsanon A., Gatechompol S., Phanuphak P., Phadungphon C., Kiertiburanakul S., Phuphuakrat A., Chumla L., Sanmeema N., Chaiwarith R., Sirisanthana T., Praparattanapan J., Nuket K., Khusuwan S., Payoong P., Kantipong P., Kambua P., Pham T.N., Nguyen K.V., Nguyen D.T.H., Nguyen D.T., Do C.D., Ngo A.V., Nguyen L.T., Sohn A.H., Ross J.L., Petersen B., Law M.G., Jiamsakul A., Rupasinghe D., the TREAT Asia HIV Observational Database of IeDEA Asia-Pacific |
57201984684;55556254800;57316129500;55406840800;7003549856;13806165200;9743902800;56166613100;57203678680;56658396600;57221273925;55553159100;57309539000;57213330022;33667461800;6506539792;57350864400;57211702929;57205894660;23007277900;57188842533;24778446900;57193109926;57196347321;57204852770;57188842644;55503803800;35796801900;57206253688;56143671100;57203375227;57350625400;57351089100;55412491000;55413091200;57213607670;35227451500;55273903300;57188839029;6602877716;57425871800;57189801547;56820043000;8935806500;6601921496;57202976978;8850357600;57202561455;57213345044;57219422563;57208428839;57202558648;57226409961;48761023600;57351205400;7601387767;57188842533;57257789600;55553159100;6603019663;55866927600;36768852500;57258598000;57207954173;36936083900;57258255400;55856943500;56514424400;57257813200;57215769524;57210531225;55992506400;57351089200;57203665233;57200282477;57193906863;7004982661;56015716600;57203677438;8277552900;56515326900;55992497800;57203665049;7004277229;35185428900;57192871045;56166613100;57350625500;6603580797;55285745100;57224761710;56370854300;57190300831;56970337500;55035577700;57208054163;41961438300;7006405275;57193720576;56406054800;57222965808;55285745500;57205313395; |
Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV |
2021 |
HIV Medicine |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119685299&doi=10.1111%2fhiv.13211&partnerID=40&md5=043ac7a37890286dc2e8fb917b3e95bc |
The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Research Institute for Tropical Medicine, Muntinlupa City, Philippines; Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS Infectious Diseases Medical Centre, VHSChennai, India; Chiang Mai University – Research Institute for Health Sciences, Chiang Mai, Thailand; National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; Faculty of Medicine, Udayana University & Sanglah Hospital, Bali, Indonesia; Bach Mai Hospital, Hanoi, Viet Nam; Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; University Malaya Medical Centre, Kuala Lumpur, Malaysia; Queen Elizabeth Hospital, Hong Kong; National Hospital for Tropical Diseases, Hanoi, Viet Nam; Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Tan Tock Seng Hospital, National Centre for Infectious Diseases, Singapore; National Center for Global Health and Medicine, Tokyo, Japan; Institute of Infectious Diseases, Pune, India; Beijing Ditan Hospital, Capital Medical University, Beijing, China; Hospital Sungai Buloh, Sungai Buloh, Malaysia; BJ Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India; TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand; Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand |
Han, W.M., The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; Law, M.G., The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; Choi, J.Y., Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Ditangco, R., Research Institute for Tropical Medicine, Muntinlupa City, Philippines; Kumarasamy, N., Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS Infectious Diseases Medical Centre, VHSChennai, India; Chaiwarith, R., Chiang Mai University – Research Institute for Health Sciences, Chiang Mai, Thailand; Ly, P.S., National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; Khusuwan, S., Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand, ; Merati, T.P., Faculty of Medicine, Udayana University & Sanglah Hospital, Bali, Indonesia; Do, C.D., Bach Mai Hospital, Hanoi, Viet Nam; Yunihastuti, E., Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Azwa, I., University Malaya Medical Centre, Kuala Lumpur, Malaysia, ; Lee, M.-P., Queen Elizabeth Hospital, Hong Kong; Pham, T.N., National Hospital for Tropical Diseases, Hanoi, Viet Nam; Chan, Y.-J., Taipei Veterans General Hospital, Taipei, Taiwan; Kiertiburanakul, S., Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Ng, O.T., Tan Tock Seng Hospital, National Centre for Infectious Diseases, Singapore; Tanuma, J., National Center for Global Health and Medicine, Tokyo, Japan; Pujari, S., Institute of Infectious Diseases, Pune, India; Zhang, F., Beijing Ditan Hospital, Capital Medical University, Beijing, China; Gani, Y., Hospital Sungai Buloh, Sungai Buloh, Malaysia, ; Mave, V., BJ Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India; Ross, J., TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand; Avihingsanon, A., HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Ly, P.S.; Khol, V.; Zhang, F.J.; Zhao, H.X.; Han, N.; Lee, M.P.; Li, P.C.K.; Kwong, T.S.; Li, T.H.; Kumarasamy, N.; Ezhilarasi, C.; Pujari, S.; Joshi, K.; Gaikwad, S.; Chitalikar, A.; Sangle, S.; Mave, V.; Marbaniang, I.; Nimkar, S.; Merati, T.P.; Wirawan, D.N.; Yuliana, F.; Yunihastuti, E.; Widhani, A.; Maria, S.; Karjadi, T.H.; Tanuma, J.; Oka, S.; Nishijima, T.; Choi, J.Y.; Na, S.; Kim, J.M.; Gani, Y.M., Hospital Sungai Buloh, Sungai Buloh, Malaysia, ; Rudi, N.B.; Azwa, I., University Malaya Medical Centre, Kuala Lumpur, Malaysia, ; Kamarulzaman, A.; SyedOmar, S.F.; Ponnampalavanar, S.; Ditangco, R.; Pasayan, M.K.; Mationg, M.L.; Chan, Y.J.; Ku, W.W.; Wu, P.C.; Ke, E.; Ng, O.T.; Lim, P.L.; Lee, L.S.; Yap, T.; Ng, O.T.; Avihingsanon, A.; Gatechompol, S.; Phanuphak, P.; Phadungphon, C.; Kiertiburanakul, S.; Phuphuakrat, A.; Chumla, L.; Sanmeema, N.; Chaiwarith, R.; Sirisanthana, T.; Praparattanapan, J.; Nuket, K.; Khusuwan, S., Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand, ; Payoong, P.; Kantipong, P.; Kambua, P.; Pham, T.N.; Nguyen, K.V.; Nguyen, D.T.H.; Nguyen, D.T.; Do, C.D.; Ngo, A.V.; Nguyen, L.T.; Sohn, A.H.; Ross, J.L.; Petersen, B.; Law, M.G.; Jiamsakul, A.; Rupasinghe, D.; the TREAT Asia HIV Observational Database of IeDEA Asia-Pacific |
Objectives: We investigated weight changes following antiretroviral therapy (ART) initiation, the development of metabolic syndrome (MetS) and its association with all-cause mortality among Asian adults living with HIV. Methods: Participants enrolled in a regional Asian HIV-infected cohort with weight and height measurements at ART initiation were eligible for inclusion in the analysis. Factors associated with weight changes and incident MetS (according to the International Diabetic Federation (IDF) definition) were analysed using linear mixed models and Cox regression, respectively. Competing-risk regression models were used to investigate the association of MetS with all-cause mortality. Results: Among 4931 people living with HIV (PLWH), 66% were male. At ART initiation, the median age was 34 [interquartile range (IQR) 29–41] years, and the median (IQR) weight and body mass index (BMI) were 55 (48–63) kg and 20.5 (18.4–22.9) kg/m2, respectively. At 1, 2 and 3 years of ART, overall mean (± standard deviation) weight gain was 2.2 (±5.3), 3.0 (±6.2) and 3.7 (±6.5) kg, respectively. Participants with baseline CD4 count ≤ 200 cells/µL [weight difference (diff) = 2.2 kg; 95% confidence interval (CI) 1.9–2.5 kg] and baseline HIV RNA ≥ 100 000 HIV-1 RNA copies/mL (diff = 0.6 kg; 95% CI 0.2–1.0 kg), and those starting with integrase strand transfer inhibitor (INSTI)-based ART (diff = 2.1 kg; 95% CI 0.7–3.5 kg vs. nonnucleoside reverse transcriptase inhibitors) had greater weight gain. After exclusion of those with abnormal baseline levels of MetS components, 295/3503 had incident MetS [1.18 (95% CI 1.05–1.32)/100 person-years (PY)]. The mortality rate was 0.7 (95% CI 0.6–0.8)/100 PY. MetS was not significantly associated with all-cause mortality in the adjusted model (P = 0.236). Conclusions: Weight gain after ART initiation was significantly higher among those initiating ART with lower CD4 count, higher HIV RNA and an INSTI-based regimen after controlling for baseline BMI. Greater efforts to identify and manage MetS among PLWH are needed. © 2021 British HIV Association |
all-cause mortality; Asian people living with HIV; HIV/AIDS; metabolic syndrome; weight gain |
|
John Wiley and Sons Inc |
14642662 |
|
34816562 |
Article |
Q1 |
1530 |
2201 |
|
|
665 |
Atmakusuma T.D., Nasution I.R., Sutandyo N. |
57216961785;8259214700;26028099200; |
Oxidative stress (Malondialdehyde) in adults beta-thalassemia major and intermedia: Comparison between before and after blood transfusion and its correlation with iron overload |
2021 |
International Journal of General Medicine |
14 |
|
|
6455 |
6462 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119614825&doi=10.2147%2fIJGM.S336805&partnerID=40&md5=31da8ca15b655debd14557088a36df4a |
Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Division of Hematology-Medical Oncology, Department of Internal Medicine, Gatot Soebroto Army Hospital Jakarta/Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Division of Hematology-Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Hospital Jakarta/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia |
Atmakusuma, T.D., Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Nasution, I.R., Division of Hematology-Medical Oncology, Department of Internal Medicine, Gatot Soebroto Army Hospital Jakarta/Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sutandyo, N., Division of Hematology-Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Hospital Jakarta/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia |
Background: Iron overload is a major problem in both transfusion-dependent (TDT) and non-transfusion-dependent thalassemia (NTDT). It has been known to increase oxidative stress. Meanwhile, blood transfusion as main therapy for thalassemia increases iron overload. One of the markers of oxidative stress is malondialdehyde (MDA). This study aims to provide data on MDA levels in adult thalassemia patients, and to compare the levels before and after transfusion in patients with TDT and NTDT. Methods: This is a cross-sectional, pre-post study in adult patients with thalassemia major and intermedia that received blood transfusion with or without iron-chelating agents in Cipto Mangunkusumo Hospital. Blood samples were taken immediately before the transfusion and one day after. Serum ferritin (SF) assays were conducted by electrochemiluminescence immunoassay method, while transferrin saturation (TS) was calculated by dividing serum iron by the binding capacity. Subsequently, plasma MDA levels assays were performed using the Wills method, and data analysis was conducted using the t-test/Mann–Whitney and Pearson/Spearman correlation test, depending on the data distribution. Results: The 63 respondents recruited consist of 51 TDT and 12 NTDT patients, and their median plasma MDA level before and after transfusion was 0.49 µmol/L and 0.45 µmol/L, respectively. Before transfusion, there was no correlation between SF and MDA, and TS and MDA levels. After the transfusion, there was no correlation between, SF and MDA, or TS and MDA levels. Conclusion: There is no significant difference in MDA levels before and after transfusion. Although blood transfusion increases the iron load in thalassemia patients, there was no increase in median MDA level after transfusion. Meanwhile, there was no correlation between markers of iron overload and MDA level in thalassemia patients both before and after transfusion. © 2021 Atmakusuma et al. This work is published and licensed by Dove Medical Press Limited. |
Iron overload; Malondialdehyde; Non-transfusion dependent thalassemia; Oxidative stress; Transfusion-dependent thalassemia |
deferasirox; deferiprone; deferoxamine; ferritin; malonaldehyde; adult; aged; Article; blood transfusion; controlled study; cross-sectional study; female; ferritin blood level; hemoglobin E-beta thalassemia; human; Indonesia; iron chelation; iron overload; major clinical study; male; non transfusion dependent thalassemia; oxidative stress; thalassemia major; transferrin saturation; transfusion dependent thalassemia |
Dove Medical Press Ltd |
11787074 |
|
|
Article |
Q2 |
722 |
6874 |
|
|
667 |
Lesmana C.R.A., Paramitha M.S., Gani R.A., Lesmana L.A. |
8977683000;57212562901;23495930300;55920139300; |
The role of endoscopic ultrasound for portal hypertension in liver cirrhosis |
2021 |
Journal of Medical Ultrasonics |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119500644&doi=10.1007%2fs10396-021-01165-4&partnerID=40&md5=72338502ade4f82a944b72db4fee4c65 |
Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Digestive Disease and GI Oncology Center, Medistra Hospital, Jakarta, Indonesia |
Lesmana, C.R.A., Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia, Digestive Disease and GI Oncology Center, Medistra Hospital, Jakarta, Indonesia; Paramitha, M.S., Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Gani, R.A., Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Lesmana, L.A., Digestive Disease and GI Oncology Center, Medistra Hospital, Jakarta, Indonesia |
Chronic liver disease is still a major problem because disease progression will ultimately lead to liver cirrhosis. Portal hypertension is the hallmark in advanced liver disease management. By establishing portal vein access, endoscopic ultrasound (EUS) has been utilized in various clinical applications. In comparison to standard upper gastrointestinal endoscopy, EUS-Doppler has been shown to be a better modality for detecting esophageal and gastric varices along with peri-esophageal collateral veins, para-esophageal collateral veins, and perforating veins, and may be used to objectively predict the recurrence of bleeding. EUS-guided portal vein catheterization has also been proposed to overcome the limitations of trans-jugular approaches. The combination of EUS-elastography and azygos vein evaluation can also enhance the diagnostic accuracy of each modality. Another well-known implementation of EUS-guided procedures is in the management of ascites; particularly in paracentesis and ascitic fluid analysis. In addition, the most common clinical application of EUS in the treatment of portal hypertension is through vascular therapy or creation of intrahepatic portosystemic shunts. Major drawbacks of EUS mainly revolve around technical difficulties, the high cost of the procedure, as well as the requirement of more studies in humans to evaluate EUS-guided advanced therapeutic modalities in portal hypertension. © 2021, The Author(s), under exclusive licence to The Japan Society of Ultrasonics in Medicine. |
Endoscopic ultrasound; Liver cirrhosis; Portal hypertension |
|
Springer |
13464523 |
|
|
Review |
#N/A |
#N/A |
#N/A |
|
|
669 |
Syafira N., Graudins A., Yarema M., Wong A. |
57222178056;55790181600;8550407600;52265101200; |
Comparing development of liver injury using the two versus three bag acetylcysteine regimen despite early treatment in paracetamol overdose |
2021 |
Clinical Toxicology |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119253032&doi=10.1080%2f15563650.2021.1998518&partnerID=40&md5=71ecde369075113c2b3f41b9bb20e452 |
Department of Medicine, School of Clinical Science at Monash Health, Monash UniversityVIC, Australia; Faculty of Medicine, Universitas Indonesia, Special Capital Region of Jakarta, Indonesia; Monash Toxicology Unit, Dandenong Hospital, Monash HealthVIC, Australia; Poison and Drug Information Service, Alberta Health Services, Calgary, Canada; Department of Emergency Medicine, University of Calgary, Calgary, Canada; Austin Toxicology Unit, Austin HealthVIC, Australia; Department of Critical Care, University of MelbourneVIC, Australia |
Syafira, N., Department of Medicine, School of Clinical Science at Monash Health, Monash UniversityVIC, Australia, Faculty of Medicine, Universitas Indonesia, Special Capital Region of Jakarta, Indonesia; Graudins, A., Department of Medicine, School of Clinical Science at Monash Health, Monash UniversityVIC, Australia, Monash Toxicology Unit, Dandenong Hospital, Monash HealthVIC, Australia; Yarema, M., Poison and Drug Information Service, Alberta Health Services, Calgary, Canada, Department of Emergency Medicine, University of Calgary, Calgary, Canada; Wong, A., Department of Medicine, School of Clinical Science at Monash Health, Monash UniversityVIC, Australia, Austin Toxicology Unit, Austin HealthVIC, Australia, Department of Critical Care, University of MelbourneVIC, Australia |
Introduction: Some studies have reported that early administration of acetylcysteine using a 3-bag regimen may not fully prevent development of liver injury in some patients. We compared the incidence of acute liver injury (ALI) in patients receiving acetylcysteine within eight hours of ingestion between the two-bag acetylcysteine regimen (200 mg/kg over four hours, 100 mg/kg over 16 h) and the three-bag regimen (150 mg/kg over 1 h, 50 mg/kg over 4 h, 100 mg/kg over 16 h). Method: This was a retrospective cohort study of the two-bag and three-bag acetylcysteine regimens from Monash Health, Victoria, Australia (2009–2020), compared to the three-bag acetylcysteine regimen data from the Canadian Acetaminophen Overdose Study (CAOS) database (1980–2005). The inclusion criteria included patients with an acute single ingestion of paracetamol; normal aminotransferases on presentation and acetylcysteine administered within eight hours post-overdose. The primary outcome was development of ALI (defined as: peak aminotransferase >150 IU/L). Results: At Monash Health, 191 patients were treated with the two-bag acetylcysteine regimen, and 180 patients with the three-bag regimen. The CAOS cohort provided 515 patients treated with the three-bag regimen. ALI developed in 1.6% (3/191) of the two-bag Monash Health group, 2.2% (4/180) of the three-bag Monash Health group (difference −0.6%, p 0.7), and 2.9% (15/515) of the three-bag CAOS group (difference compared to two-bag −1.3%, p 0.4). Hepatotoxicity (ALT >1000) developed in 0.5% (1/191) of patients treated with the two-bag regimen, 1.7% (3/180) in the Monash Health three-bag regimen and 1% (5/515) of the three-bag CAOS group. There were no statistically significant differences between groups. Conclusions: ALI and hepatotoxicity were observed in a small, comparable percentage of patients despite early acetylcysteine administration using the two-bag and three-bag regimens. Repeating blood tests at the end of acetylcysteine treatment will identify these patients and indicate those requiring continuation of acetylcysteine. © 2021 Informa UK Limited, trading as Taylor & Francis Group. |
Acetaminophen; acute liver injury; hepatotoxicity |
|
Taylor and Francis Ltd. |
15563650 |
|
|
Article |
Q2 |
840 |
5641 |
|
|
671 |
Irawan C., Rachman A., Rahman P., Mansjoer A. |
28767651600;15056701600;57336745700;24335647800; |
Role of Pretreatment Hemoglobin-to-Platelet Ratio in Predicting Survival Outcome of Locally Advanced Nasopharyngeal Carcinoma Patients |
2021 |
Journal of Cancer Epidemiology |
2021 |
|
1103631 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118993816&doi=10.1155%2f2021%2f1103631&partnerID=40&md5=82e487803fe00d9c97bbac4301d585e1 |
Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Clinical Epidemiology Unit, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Irawan, C., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rachman, A., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rahman, P., Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Mansjoer, A., Clinical Epidemiology Unit, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Background. The three-year survival rate of locally advanced nasopharyngeal carcinoma (NPC) patients in Indonesia is lower than in other Asian countries. Calculation of hemoglobin-to-platelet ratio (HPR) may become a more practical predictor than the ratios using leukocyte cell components. Yet, no study has been conducted to investigate the potential of HPR in predicting survival outcomes in locally advanced nasopharyngeal cancer patients. Objective. To determine the role of pretreatment hemoglobin-to-platelet ratio in predicting the three-year overall survival (OS) of locally advanced NPC. Method. A retrospective cohort study followed up on 289 locally advanced NPC patients who had undergone therapy at the Dr. Cipto Mangunkusumo National General Hospital between January 2012 and October 2016. HPR cut-off was determined using ROC. Subjects were classified into two groups according to the HPR value. Kaplan-Meier curve was utilized to illustrate patients' three-year survival, and Cox regression test analyzed confounding variables to yield an adjusted hazard ratio (HR). Results. The optimal cut-off for HPR was 0.362 (AUC 0.6228, 95% CI: 0.56-0.69, sensitivity 61.27%, specificity 60.34%). Of the subjects, 48.44% had HPR≤0.362, and they had a higher three-year mortality rate than those with HPR>0.362 (50% vs. 31.54%). In bivariate analysis, HPR≤0.362 and age≥60 significantly showed a worse three-year OS (p value = 0.003 and 0.075, respectively). In multivariate analysis, we concluded that a pretreatment HPR≤0.362 was an independent negative predictor of three-year OS in locally advanced NPC patients (adjusted HR 1.82; 95% CI: 1.25-2.65). Conclusion. Pretreatment HPR≤0.362 was a negative predictor of three-year OS in locally advanced nasopharyngeal cancer patients. © 2021 Cosphiadi Irawan et al. |
|
antineoplastic agent; hemoglobin; adjuvant therapy; adult; advanced cancer; area under the curve; Article; cancer chemotherapy; cancer mortality; cancer patient; cancer prognosis; cancer radiotherapy; cancer survival; clinical outcome; cohort analysis; conformal radiotherapy; controlled study; female; follow up; general hospital; hematological parameters; hemoglobin blood level; hemoglobin to platelet ratio; human; human cell; intensity modulated radiation therapy; locally advanced nasopharyngeal carcinoma; major clinical study; male; middle aged; multiple cycle treatment; nasopharynx carcinoma; neoadjuvant chemotherapy; nutritional status; overall survival; platelet count; receiver operating characteristic; reference value; retrospective study; sensitivity and specificity; survival predic |
Hindawi Limited |
16878558 |
|
|
Article |
Q2 |
783 |
6201 |
|
|
672 |
Tunjungputri R.N., Tetrasiwi E.N., Veronica M., Pandelaki J., Ibrahim F., Nelwan E.J. |
56342194400;57267704700;57268337000;35759266900;54886001500;14527452900; |
Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19 |
2021 |
Case Reports in Medicine |
2021 |
|
9673453 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118971098&doi=10.1155%2f2021%2f9673453&partnerID=40&md5=ddb9dd4ce5b8de10f0e4c9c43c6cd496 |
Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Radiology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Microbiology Department, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Infectious Disease and Immunology Research Center - IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Tunjungputri, R.N., Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Tetrasiwi, E.N., Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Veronica, M., Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Pandelaki, J., Department of Radiology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Ibrahim, F., Microbiology Department, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Nelwan, E.J., Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia, Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia, Infectious Disease and Immunology Research Center - IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Introduction. The COVID-19 pandemic has entered a new phase with the roll-out of several vaccines worldwide at an accelerated phase. The occurrence of a more severe presentation of COVID-19 after vaccination may affect policymakers' decision-making and vaccine uptake by the public. Vaccine-associated disease enhancement (VADE) is the modified presentation of infections in individuals after having received a prior vaccination. Currently, little is known about the potential of vaccine-associated disease enhancement (VADE) following COVID-19 immunization. Case Illustration. We herewith report two patients admitted with confirmed COVID-19 pneumonia with a history of CoronaVac vaccination. The first patient with a relatively milder course of the disease had received two doses of CoronaVac, whereas the second patient with a more progressive course of the disease received only one dose before developing symptoms and being admitted to the hospital. Our observations suggest that vaccination could act in boosting the inflammatory process and reveal the previously asymptomatic COVID-19 illness. Theoretically, vaccines could induce VADE, where only suboptimal, nonprotective titers of neutralizing antibodies were produced or proinflammatory T-helper type 2 response was induced. Secondly, enhanced respiratory disease (ERD) could manifest, where pulmonary symptoms are more severe due to peribronchial monocytic and eosinophilic infiltration. Understanding VADE is important for the decision-making by the public, clinicians, and policymakers and is warranted for successful vaccination uptake. Conclusion. We report two cases of patients developing COVID-19 shortly after CoronaVac vaccination in which VADE is likely. We recommend that current vaccination strategies consider the measurement of neutralizing antibody titer as a guide in ensuring the safest strategy for mass immunization. Studies are needed to investigate the true incidence of VADE on vaccinated individuals as well as on how to differentiate between VADE and severe manifestations of COVID-19 that are unrelated to vaccination. © 2021 Rahajeng N. Tunjungputri et al. |
|
C reactive protein; coronavac; D dimer; fibrinogen; hemoglobin; neutralizing antibody; procalcitonin; adult; antibody titer; Article; asymptomatic coronavirus disease 2019; blood pressure; calcitonin blood level; case report; clinical article; coronavirus disease 2019; COVID-19 testing; electrocardiography; fibrinogen blood level; heart right bundle branch block; hemoglobin blood level; hospital admission; human; hyperglycemia; hypokalemia; hyponatremia; hypoosmolarity; inflammation; laboratory test; leukocyte count; lung examination; male; medical history; middle aged; physical examination; platelet count; protein blood level; real time polymerase chain reaction; thorax radiography; vaccination; vaccine associated disease enhancement; vaccine associated disease enhancement; young adult |
Hindawi Limited |
16879627 |
|
|
Article |
Q4 |
200 |
19317 |
|
|